secwatch.observer — SEC 8-K summary
======================================

Issuer:     MESA LABORATORIES INC /CO/ (MLAB)
CIK:        0000724004
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001437749-23-030284
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mesa Labs Q2 revenue down 9.5% to $53.2M, net loss of $1.23M
------------------------------------------------------------

- Operating income turned negative at $(60), down 101.5% vs prior year.
- Non-GAAP adj. operating income ex unusual items fell 29.1% to $11.2M.
- Clinical Genomics down 15.7% organic on Sema4 loss ($8.2M annual headwind).
- Biopharm Development revenues fell 24.4% organic, consumables up 4.7%.
- Cost actions expected to save ~$2M annually starting in Q3; GKE acquisition closed Oct 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/724004/000143774923030284/0001437749-23-030284-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/724004/000143774923030284/mlab20231103_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-030284

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer